GlassScriptPhysician profile
Robert W Schuman
NPI 1689774713
$38,975.63
in general payments reported to CMS, 2019-2025
44 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,342 · 2020: $1,619 · 2021: $5,769 · 2022: $14K · 2023: $8,132 · 2024: $5,808 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,417 · Food and Beverage: $6,371 · Consulting Fee: $600 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,417.00 |
| Food and Beverage | $6,371.08 |
| Consulting Fee | $600.00 |
| Education | $105.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22,922.65 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,272.53 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $2,569.52 | 2021-2024 | Zeposia |
| Abbvie INC. | $2,265.35 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,588.82 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $837.31 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $797.42 | 2019-2025 | |
| Gilead Sciences, INC. | $619.70 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $574.41 | 2019-2025 | Linzess |
| Merck Sharp & Dohme LLC | $379.65 | 2019-2024 | Dificid, Zerbaxa |
| Evoke Pharma, INC. | $370.60 | 2020-2025 | Gimoti |
| Braintree Laboratories, INC. | $321.89 | 2019-2025 | Suflave |
| Daiichi Sankyo INC. | $277.68 | 2019-2022 | |
| Ardelyx, INC. | $222.11 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $205.70 | 2019-2025 | Ocaliva |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $201.64 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $192.40 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $187.79 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Regeneron Healthcare Solutions, INC. | $113.44 | 2024-2025 | Dupixent |
| Vivus LLC | $107.28 | 2019-2024 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $103.50 | 2020-2023 | |
| Celltrion USA INC. | $102.00 | 2023-2025 | Vegzelma, Yuflyma |
| Phathom Pharmaceuticals, INC. | $98.74 | 2024-2025 | Voquezna |
| Intra-Sana Laboratories | $97.79 | 2022-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Genzyme Corporation | $76.00 | 2022-2024 | |
| Madrigal Pharmaceuticals | $67.30 | 2024-2025 | Resmetirom, Rezdiffra |
| Ucb, INC. | $39.76 | 2019 | |
| Novo Nordisk INC | $36.70 | 2025 | Wegovy |
| Medtronic, INC. | $34.99 | 2021-2024 | Endoflip |
| Fresenius Kabi USA, LLC | $34.49 | 2023-2024 | Idacio |
| Sandoz INC. | $32.06 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $31.26 | 2025 | Zenpep |
| Qol Medical, LLC | $28.57 | 2021 | |
| Pharmacosmos Therapeutics INC. | $24.96 | 2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $16.95 | 2025 | Iqirvo |
| Organon LLC | $16.56 | 2023 | Renflexis |
| Olympus America INC. | $15.74 | 2019 | |
| Capsovision, INC. | $15.16 | 2024 | Capsocam Plus |
| Endo Pharmaceuticals INC. | $15.00 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.15 | 2023 | Kristalose |
| W. L. Gore & Associates, INC. | $13.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2023 | Cyltezo |
| Echosens North America, INC. | $11.33 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $7.74 | 2023 | Blueboost |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.